Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Preclinical Assessment of Non-Virally Engineered CD33.CAR Cytokine-Induced Killer (CIK) Cells in Chemoresistant AML Patient-Derived Xenografts

Maria Caterina Rotiroti, PhD, Chiara Buracchi, PhD, Silvia Arcangeli, PhD, Chiara F Magnani, PhD, Claudia Cappuzzello, PhD, Zsuzsanna Izsvak, PhD, Stefania Galimberti, PhD, Maria Grazia Valsecchi, PhD, Giuseppe Dastoli, MD, Marta Serafini, PhD, Ettore Biagi, MD, Andrea Biondi, MD, Sarah Tettamanti, PhD

Blood (2019) 134 (Supplement_1): 2665.

https://doi.org/10.1182/blood-2019-130399

Published: 2019

Journal Articles

Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2019) 134 (Supplement_1): 200.

https://doi.org/10.1182/blood-2019-125894

Published: 2019

Journal Articles

Downregulation of Sprr1a Contributes to the Pathobiology of Sickle Cell Disease

Donovan A Argueta, BSc, Anupam Aich, PhD, Jianxun Lei, PhD, Sergei Nekhai, PhD, Tatiana Ammosova, PhD, Xionghao Lin, PhD, Anindya Bagchi, PhD, Kalpna Gupta, PhD

Blood (2019) 134 (Supplement_1): 75.

https://doi.org/10.1182/blood-2019-129004

Published: 2019

Journal Articles

Piggybac CD19 CAR T Cells Eradicate CNS Leukemia By Direct Delivery into Cerebral Ventricle of Xenograft Mice Model

Kuniaki Tanaka, MD, Itaru Kato, MD, PhD, Miyuki Tanaka, MD, PhD, Daisuke Morita, MD, PhD, Yoshiyuki Takahashi, MD, PhD, Tatsutoshi Nakahata, MD, PhD, Katsutsugu Umeda, MD, PhD, Hidefumi Hiramatsu, MD, PhD, Souichi Adachi, MD PhD, Junko Takita, MD, PhD, Yozo Nakazawa, MD, PhD

Blood (2018) 132 (Supplement 1): 4028.

https://doi.org/10.1182/blood-2018-99-111733

Published: 2018

Journal Articles

The HACE1-NRF2 Axis a Novel Target in Acute Myeloid Leukemia

Andoni Garitano-Trojaola, PhD, Eva Teufel, Nadine Rodhes, Jennifer Kreckel, Thorsten Stuehmer, Matteo Claudio Da Via', MD, Santiago Barrio Garcia, PhD, Torsten Haferlach, MD, Raoul Tibes, Harald Wajant, Andreas Rosenwald, Hermann Einsele, MD, K. Martin Kortüm, MD

Blood (2018) 132 (Supplement 1): 5132.

https://doi.org/10.1182/blood-2018-99-118270

Published: 2018

Journal Articles

Enhancing Human NK Cell Function and Specificity for Cancer Immunotherapy

Pomeroy Emily, Hunzeker John, Kluesner Mitchell, Crosby Margaret, Laura Bendzick, Jeffrey S. Miller, MD, Beau Webber, PhD, Melissa A. Geller, Martin Felices, PhD, Tim Starr, Branden S Moriarity, PhD

Blood (2018) 132 (Supplement 1): 2044.

https://doi.org/10.1182/blood-2018-99-120173

Published: 2018

Journal Articles

Specific Targeting of Acute Myeloid Leukemia By the Use of Non-Virally Engineered CIK (Cytokine-Induced Killer) Cells Expressing the Anti-CD33 Chimeric Antigen Receptor (CAR)

Maria Caterina Rotiroti, MSc, Silvia Arcangeli, PhD, Chiara Buracchi, PhD, Chiara Francesca Magnani, PhD, Claudia Cappuzzello, PhD, Ettore Biagi, MD, Sarah Tettamanti, PhD, Andrea Biondi, MD

Blood (2018) 132 (Supplement 1): 2201.

https://doi.org/10.1182/blood-2018-99-114572

Published: 2018

Journal Articles

Clinical-Grade Transduction of Allogeneic Cytokine Induced Killer (CIK) Cells with CD19 Chimeric Antigen Receptor (CAR) Using Sleeping Beauty (SB) Transposon: Successful GMP-Compliant Manufacturing for Clinical Applications

Blood (2018) 132 (Supplement 1): 196.

https://doi.org/10.1182/blood-2018-196

Published: 2018

Journal Articles

Interleukin 21 Enhances Survival and Expansion of CAR T Cells Via Inhibition of Their Terminal Differentiation during Interaction with Tumor Target Cells

Martin Štach, Jan Musil, Petr Cetkovsky, MD MBA, PhD, Pavel Otahal, MD PhD

Blood (2018) 132 (Supplement 1): 4545.

https://doi.org/10.1182/blood-2018-99-116294

Published: 2018

Journal Articles

Defining the Transcriptional Code That Specifies Sinusoidal Endothelial Cells in the HSPC Niche

Elliott J. Hagedorn, PhD, Julie R. Perlin, PhD, Clara Mao, Shelby E. Redfield, B.S., Madeleine L. Daily, B.S., Samantha H. Collins, B.S., Christopher R. D'Amato, B.S., Raquel Riquelme, Brian Li, B.S., Samuel J. Wattrus, B.S., Karoline Holler, B.S., Alexander van Oudenaarden, PhD, Jan Philipp Junker, PhD, Leonard I. Zon, MD

Blood (2017) 130 (Supplement 1): 136.

https://doi.org/10.1182/blood.V130.Suppl_1.136.136

Published: 2017

Journal Articles

Long Term Follow up after Adoptive Transfer of CD19-Specific CAR + T Cells Genetically Modified Via Non-Viral Sleeping Beauty S ystem Following Hematopoietic Stem Cell Transplantation (HSCT)

Blood (2017) 130 (Supplement 1): 2059.

https://doi.org/10.1182/blood.V130.Suppl_1.2059.2059

Published: 2017

Journal Articles

Shortening the Time to Manufacture CAR + T Cells with Sleeping Beauty System Supports T-Cell Engraftment and Anti-Tumor Effects in Patients with Refractory CD19 + Tumors

Partow Kebriaei, MD, Helen Huls, Susan Lynn Neel, RN, OCN, Simon Olivares, Aaron F Orozco, Shihuang Su, Sourindra N Maiti, Amy Smith, Elenanor De Groot, Hagop M. Kantarjian, MD, Maro Ohanian, DO, Katy Rezvani, MD PhD, Elizabeth J Shpall, MD, Richard E Champlin, MD, Laurence J N Cooper, MDPhD, Harjeet Singh, MSc, PhD

Blood (2017) 130 (Supplement 1): 2060.

https://doi.org/10.1182/blood.V130.Suppl_1.2060.2060

Published: 2017

Journal Articles

The Application of ‘Drug-Reversible’ CAR-T Cells Directed Against Recipient Hematopoietic Cells As a Selective Conditioning Strategy for Stem Cell Transplantation

Nina Timberlake, Maximilian Richter, Xinxin Wang, PhD, Nicholas Cam, Yening Tan, Eric M Ostertag, Devon J Shedlock, Julian D Down

Blood (2017) 130 (Supplement 1): 1893.

https://doi.org/10.1182/blood.V130.Suppl_1.1893.1893

Published: 2017

Journal Articles

B-Cell Maturation Antigen (BCMA)-Specific, Centyrin TM -Based, PiggyBac TM -Transposed CAR-T Memory Stem Cells Are Effective Against p53 -/- and Patient-Derived Multiple Myeloma Tumors

Blood (2017) 130 (Supplement 1): 3068.

https://doi.org/10.1182/blood.V130.Suppl_1.3068.3068

Published: 2017

Journal Articles

Sleeping Beauty Modified CAR+ Lymphocytes Engraft and Exhibit Anti-Tumor Activity in Patient-Derived Xenograft Models of Acute Lymphoblastic Leukemia

Chiara F. Magnani, PhD, Claudia Mezzanotte, Claudia Cappuzzello, PhD, Fabrizio Benedicenti, Michela Bardini, PhD, Sarah Tettamanti, PhD, Grazia Fazio, PhD, Gianni Cazzaniga, PhD, Laurence J.N. Cooper, MD PhD, Eugenio Montini, PhD, Andrea Biondi, MD, Ettore Biagi, MD PhD

Blood (2016) 128 (22): 4022.

https://doi.org/10.1182/blood.V128.22.4022.4022

Published: 2016

Journal Articles

Dna Methylation Is Linked to a Specific Cell-Adhesion Program in Relapsed Pediatric t(8;21)(q22;q22) RUNX1-RUNX1T1 Patients

Matteo Zampini, PhD, Claudia Tregnago, PhD, Valeria Bisio, PhD, Benedetta Accordi, PhD, Valentina Serafin, PhD, Paolo Pierani, MD, Nicola Santoro, MD, Marco Zecca, MD, Concetta Micalizzi, MD, Maria Caterina Putti, MD, Franco Locatelli, MD, Giuseppe Basso, Martina Pigazzi, PhD

Blood (2016) 128 (22): 1524.

https://doi.org/10.1182/blood.V128.22.1524.1524

Published: 2016

Journal Articles

Engineering Human Pluripotent Stem Cell-Derived Natural Killer Cells to Prevent CD16a Shedding for Enhanced Anti-Tumor Killing

Robert Blum, MS, Aadithya Arumugam, PhD, Jianming Wu, DVM, PhD, Bruce Walcheck, PhD, Dan Kaufman, MD PhD

Blood (2016) 128 (22): 1336.

https://doi.org/10.1182/blood.V128.22.1336.1336

Published: 2016

Journal Articles

A Novel Bcma-Specific, Centyrin-Based CAR-T Product for the Treatment of Multiple Myeloma

David L. Hermanson, PhD, Burton Earle Barnett, PhD, Srinivas Rengarajan, M.S., Rebecca Codde, B.S., Xinxin Wang, PhD, Yening Tan, B.S., Christopher E. Martin, PhD, Jenessa Barbara Smith, PhD, Jin He, M.S., Rohit Mathur, PhD, Jing Yan, PhD, Sattva S. Neelapu, MD, Eric M. Osertag, MD PhD, Devon J. Shedlock, PhD

Blood (2016) 128 (22): 2127.

https://doi.org/10.1182/blood.V128.22.2127.2127

Published: 2016

Journal Articles

piggyBac TM -Produced CAR-T Cells Exhibit Stem-Cell Memory Phenotype

Burton Earle Barnett, PhD, David L. Hermanson, PhD, Jenessa Barbara Smith, PhD, Xinxin Wang, PhD, Yening Tan, B.S., Christopher E. Martin, PhD, Eric M. Osertag, MD PhD, Devon J. Shedlock, PhD

Blood (2016) 128 (22): 2167.

https://doi.org/10.1182/blood.V128.22.2167.2167

Published: 2016

Journal Articles

Personalization of T-Cell Therapy Using a High-Throughput Platform to Identify Tumor-Specific T-Cell Receptors

Shan Zong, PhD, Laurence J.N. Cooper, MD PhD, George T McNamara, PhD, Hiroki Torikai, MD

Blood (2016) 128 (22): 3359.

https://doi.org/10.1182/blood.V128.22.3359.3359

Published: 2016

NARROW

Preclinical Assessment of Non-Virally Engineered CD33.CAR Cytokine-Induced Killer (CIK) Cells in Chemoresistant AML Patient-Derived Xenografts

Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Downregulation of Sprr1a Contributes to the Pathobiology of Sickle Cell Disease

Piggybac CD19 CAR T Cells Eradicate CNS Leukemia By Direct Delivery into Cerebral Ventricle of Xenograft Mice Model

The HACE1-NRF2 Axis a Novel Target in Acute Myeloid Leukemia

Enhancing Human NK Cell Function and Specificity for Cancer Immunotherapy

Specific Targeting of Acute Myeloid Leukemia By the Use of Non-Virally Engineered CIK (Cytokine-Induced Killer) Cells Expressing the Anti-CD33 Chimeric Antigen Receptor (CAR)

Clinical-Grade Transduction of Allogeneic Cytokine Induced Killer (CIK) Cells with CD19 Chimeric Antigen Receptor (CAR) Using Sleeping Beauty (SB) Transposon: Successful GMP-Compliant Manufacturing for Clinical Applications

Interleukin 21 Enhances Survival and Expansion of CAR T Cells Via Inhibition of Their Terminal Differentiation during Interaction with Tumor Target Cells

Defining the Transcriptional Code That Specifies Sinusoidal Endothelial Cells in the HSPC Niche

Long Term Follow up after Adoptive Transfer of CD19-Specific CAR + T Cells Genetically Modified Via Non-Viral Sleeping Beauty S ystem Following Hematopoietic Stem Cell Transplantation (HSCT)

Shortening the Time to Manufacture CAR + T Cells with Sleeping Beauty System Supports T-Cell Engraftment and Anti-Tumor Effects in Patients with Refractory CD19 + Tumors

The Application of ‘Drug-Reversible’ CAR-T Cells Directed Against Recipient Hematopoietic Cells As a Selective Conditioning Strategy for Stem Cell Transplantation

B-Cell Maturation Antigen (BCMA)-Specific, Centyrin TM -Based, PiggyBac TM -Transposed CAR-T Memory Stem Cells Are Effective Against p53 -/- and Patient-Derived Multiple Myeloma Tumors

Sleeping Beauty Modified CAR+ Lymphocytes Engraft and Exhibit Anti-Tumor Activity in Patient-Derived Xenograft Models of Acute Lymphoblastic Leukemia

Dna Methylation Is Linked to a Specific Cell-Adhesion Program in Relapsed Pediatric t(8;21)(q22;q22) RUNX1-RUNX1T1 Patients

Engineering Human Pluripotent Stem Cell-Derived Natural Killer Cells to Prevent CD16a Shedding for Enhanced Anti-Tumor Killing

A Novel Bcma-Specific, Centyrin-Based CAR-T Product for the Treatment of Multiple Myeloma

piggyBac TM -Produced CAR-T Cells Exhibit Stem-Cell Memory Phenotype

Personalization of T-Cell Therapy Using a High-Throughput Platform to Identify Tumor-Specific T-Cell Receptors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only